Hycor casts off urinalysis to focus on allergy and autoimmune testing
This article was originally published in Clinica
Executive Summary
In vitro diagnostics firm Hycor has divested its urinalysis business in a bid to focus on the faster-growing allergy and autoimmune sectors. The unit, sold to a private equity consortium comprising One Rock Capital Partners, Laurel Crown Partners and StoneCreek Capital, includes Hycor's KOVA urinalysis products; the new business will be named Kova International and will be led by former Hycor executive Vance Mitchell. Financial terms were not disclosed.